The Vanguard Group, Inc. recently announced the acquisition of new stake in Phibro Animal Health Corporation (NASDAQ:PAHC). The institutional investor has increased its shareholding in the Healthcare company by 1.68% to 2.26 million shares with purchase of 37431.0 shares. This fresh investment now brings its stake to 11.13% valued currently at $30.36 million. In addition, SSgA Funds Management, Inc. raised its holdings by 23483.0 to 0.89 million shares. And Millennium Management LLC has lifted its position by 1,923.83% or 0.62 million shares – to 0.66 million shares.
With over 0.14 million Phibro Animal Health Corporation (PAHC) shares trading Monday and a closing price of $15.44 on the day, the dollar volume was approximately $2.2 million. The shares have shown a negative half year performance of -22.14% and its price on 01/23/23 gained nearly 0.72%. Currently, there are 40.50M common shares owned by the public and among those 20.23M shares have been available to trade.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 4 analysts who have offered their price forecasts for PAHC have a consensus price objective of $16.75. The analysts have set the share’s price value over the next 12 months at a high of $20.00 and a low of $12.00. The average price target is 7.82% above its recent price level and a downside to the estimated low will see the stock lose -28.67% over that period. But an upside of 22.8% will see the stock hit the forecast high price target while median target price for the stock is $17.50.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Phibro Animal Health Corporation are iShares Core S&P Small Cap ETF, Heartland Group Inc. – Value Plus, and Vanguard Total Stock Market Index. iShares Core S&P Small Cap ETF owns 1.5 million shares of the company’s stock, all valued at over $20.18 million. The company sold 1144.0 shares recently to bring their total holdings to about 7.40% of the shares outstanding. Vanguard Total Stock Market Index now owns shares totaling to 2.82% of the shares outstanding.
Shares of Phibro Animal Health Corporation (NASDAQ: PAHC) opened at $15.19, down -$0.14 from a prior closing price of $15.33. However, the script later moved the day high at 15.69, up 0.72%. The company’s stock has a 5-day price change of 5.11% and 10.76% over the past three months. PAHC shares are trading 15.14% year to date (YTD), with the 12-month market performance down to -22.02% lower. It has a 12-month low price of $11.75 and touched a high of $22.16 over the same period. PAHC has an average intraday trading volume of 164.14K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 9.69%, 15.67%, and -5.56% respectively.
Institutional ownership of Phibro Animal Health Corporation (NASDAQ: PAHC) shares accounts for 99.40% of the company’s 40.50M shares outstanding. Mutual fund holders own 52.80%, while other institutional holders and individual stakeholders account for 9.04% and 46.08% respectively.
It has a market capitalization of $621.77M and a beta (3y monthly) value of 0.54. The stock’s trailing 12-month PE ratio is 13.45, while the earnings-per-share (ttm) stands at $1.15. The company has a PEG of 3.74 and a Quick Ratio of 1.70 with the debt-to-equity ratio at 1.78. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.22% over the week and 3.52% over the month.
Analysts forecast that Phibro Animal Health Corporation (PAHC) will achieve an EPS of $0.26 for the current quarter, $0.32 for the next quarter and $1.52 for 2024. The lowest estimate earnings-per-share for the quarter is $0.24 while analysts give the company a high EPS estimate of $0.3. Comparatively, EPS for the current quarter was $0.25 a year ago. Earnings per share for the fiscal year are expected to decrease by -9.60%, and 13.42% over the next financial year. EPS should grow at an annualized rate of 3.60% over the next five years, compared to -5.50% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 4 brokerage firm advisors rate Phibro Animal Health Corporation (PAHC) as a “Hold” at a consensus score of 3.20. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 1 of the 4 advise that investors “hold,” and 1 rated it as a “Sell.”
Looking at the support for the PAHC, a number of firms have released research notes about the stock. ROTH Capital stated their Buy rating for the stock in a research note on December 21, 2022, with the firm’s price target at $18. Barclays coverage for the Phibro Animal Health Corporation (PAHC) stock in a research note released on July 25, 2022 offered a Underweight rating with a price target of $22. Barclays was of a view on January 10, 2022 that the stock is Equal Weight, while Morgan Stanley gave the stock Equal-Weight rating on November 18, 2021, issuing a price target of $23. Credit Suisse on their part issued Neutral rating on August 05, 2021.
